Immunohistrochemistry Expression of COX-2 as a Prognostic Factor for Survival in Locally Advanced Cervical Cancer Treated with Concurrent Cisplatin-Radiation Therapy

Authors

  • Jiraporn Setakornnukul

Abstract

Objective: Cervical cancer is a major health problem for women. Concurrent Cisplatin-radiation therapy (CCRT) can improve survival, although result of treatment is still not satisfactory.   Many prognostic factors have been known, but they cannot explain all the results. Cyclooxygenase-2 (COX-2) is one of the molecular factors related to angiogenesis that can lead to more accurate predictive outcome and modification of the treatment in the future.
Methods: Retrospective study to find relationship of COX-2 expression to overall survival (OS), progression free survival (PFS), distant metastasis free survival (DMFS), and loco-regional relapse free survival (LRRFS) of locally advanced cervical cancer in patients who were treated with CCRT at Siriraj Hospital from 2002 to 2007. In this COX-2 IHC study, the interpretations of results were based on both intensity and quantity score.
Results: There were 49 patients included into the study. COX-2 was positive in 36 (73%).    Median f/u time was 22 months.   COX-2 expression was proven to be a significant prognostic factor to predict OS and PFS with HR 19.5 (95% CI 1.1-337.2) and HR 27.1 (95% CI 2.1-355.6) respectively. Total treatment time (>55 days) is the most significant prognostic factor for OS, PFS and DMF.   
Conclusion: Expression of COX-2 positive is a significant prognostic factor to predict worse OS and PFS compared to COX-2 negative group in multivariate analysis. The COX-2 scoring system used in this study was good to predict prognosis.

Keywords: Locally advanced cervical cancer, expression of COX-2, prognosis factor, concurrent chemo-radiotherapy

Downloads

Published

26-11-2014

How to Cite

Setakornnukul, J. (2014). Immunohistrochemistry Expression of COX-2 as a Prognostic Factor for Survival in Locally Advanced Cervical Cancer Treated with Concurrent Cisplatin-Radiation Therapy. Siriraj Medical Journal, 66(5). Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/55278

Issue

Vol. 66 No. 5 (2014): September-October

Section

Original Article

License

Authors who publish with this journal agree to the following conditions:

Copyright Transfer

In submitting a manuscript, the authors acknowledge that the work will become the copyrighted property of Siriraj Medical Journal upon publication.

License

 Articles are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). This license allows for the sharing of the work for non-commercial purposes with proper attribution to the authors and the journal. However, it does not permit modifications or the creation of derivative works.

Sharing and Access

Authors are encouraged to share their article on their personal or institutional websites and through other non-commercial platforms. Doing so can increase readership and citations.